Pfizer to buy Metsera in deal worth up to $10 billion

Market Focus - The company identifies obesity as a very fast-growing market with significant potential for value creation [1][2] Strategic Acquisition - The company acquired an advanced portfolio in the obesity market after evaluating opportunities in the US, Europe, and China [1] - The acquisition includes a contingent value right for Metser shareholders, linked to achieving specific milestones such as phase three approvals [3] Core Competencies - The company possesses strengths in conducting large, complex studies, particularly in metabolic cardiovascular comorbidities [3] - The company has strong commercial capabilities in promoting relevant medicines [4] - The company has robust manufacturing capabilities, addressing a potential bottleneck [4] Strategic Rationale - The company aims to leverage its capabilities to maximize the value of the acquired portfolio [2] - The company's existing portfolio was not successful, necessitating the acquisition to secure a promising portfolio [4]